Patents Ordinance, 2000

What it is

The Patents Ordinance, 2000 replaced the patents provisions of the Patents and Designs Act, 1911 and brought Pakistani patent law into line with TRIPS. It provides for the grant of patents for inventions that are new, involve an inventive step and are capable of industrial application, with a term of twenty years from the filing date, subject to payment of renewal fees. It sets out what is not patentable — including discoveries, mathematical methods and methods of medical treatment [the precise exclusions TO BE VERIFIED BY REVIEWING LAWYER] — and it extends product patent protection to pharmaceuticals and agricultural chemicals, which the 1911 regime had not. The Ordinance provides for opposition and revocation proceedings, compulsory licensing on statutory grounds, and infringement actions with the usual civil remedies.

Applications are filed with the Patent Office, which examines and grants; the Office is administered by the Intellectual Property Organization of Pakistan, and enforcement litigation lies before the IP tribunals constituted under the Intellectual Property Organization of Pakistan Act, 2012. Foreign applicants file directly in Pakistan claiming Paris Convention priority, because Pakistan was not, to the firm's knowledge, a contracting state of the Patent Cooperation Treaty as of early 2026 — there is no PCT national-phase route into Pakistan [accession status as of mid-2026 TO BE VERIFIED BY REVIEWING LAWYER].

What changed

The principal amendment is the Patents (Amendment) Ordinance, 2002, which completed the TRIPS alignment — including the transitional arrangements for pharmaceutical and agrochemical applications and exclusive marketing rights required by TRIPS during the transition [the current operative effect of those transitional provisions TO BE VERIFIED BY REVIEWING LAWYER]. Since 2002 the text has been broadly stable, and the changes have been institutional: administration consolidated under IPO-Pakistan in 2012, litigation routed to the IP tribunals, and staged digitisation of filing and the patent journal. Two reform threads should be checked as of mid-2026: reported proposals to amend the Ordinance or replace it with a new patents law, and Pakistan's long-discussed accession to the PCT, either of which would change filing strategy materially [both TO BE VERIFIED BY REVIEWING LAWYER].

Who is affected

The Ordinance matters most to the pharmaceutical industry — originators seeking and enforcing product patents, and generic manufacturers assessing freedom to operate and challenging grants — and to manufacturers, engineering firms and technology companies protecting processes and products in the Pakistani market. Foreign patentees hold a large share of granted Pakistani patents and enforce through local counsel before the IP tribunals. Licensees, contract manufacturers and importers are affected through the chain: a patent in force against a product reaches everyone dealing in it.

What to do

For inventions with Pakistani market value, file in Pakistan within the twelve-month Paris priority window, because the missing PCT route means the decision cannot be deferred to a national-phase deadline. Calendar renewal fees for the full term — lapse for non-payment is the commonest way Pakistani patents die [the renewal schedule and restoration provisions TO BE VERIFIED BY REVIEWING LAWYER]. Before launching a product, run a freedom-to-operate check against granted patents and pending published applications, and consider opposition or revocation where a blocking grant looks vulnerable. Patent owners should record assignments and licences with the Patent Office and act on infringement promptly before the IP tribunal, where interim relief carries most of the practical value. Track the PCT and amendment questions with counsel before setting multi-year filing strategy.